Market Announcement 23 October 2026 Resonance Health Limited (ASX: RHT) – Trading Halt Trading in the securities of Resonance Health Limited (‘RHT’) will be halted at the request of RHT, pending the release of an announcement by RHT. Unless ASX decides otherwise, the securities will remain in...
Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Resonance Health Ltd has requested a trading halt for its securities pending an announcement regarding market-sensitive information. The halt will remain in effect until normal trading resumes or the announcement is released, whichever comes first. The announcement is expected to cover preliminary results from a clinical trial and a placement to investors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-1782
Release
Earlier from Resonance Health
- Notice of Annual General Meeting/Proxy Form
- Liver Fibrosis Device - Clinical Trial Results - Webinar
- AGM Date & Director Nomination Closing Date
- Change in Substantial Holding
- Global Strategic Alliance & MSA with Image Analysis Group
Later from Resonance Health
- Liver Fibrosis Device - EPoC Study Results
- $6.0 Million Placement Oversubscribed
- Proposed issue of securities - RHT
- Investor Presentation Liver Fibrosis Device & Capital Raise
- Liver Fibrosis Device Webinar Presentation
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health